Premature discontinuation of antiplatelet therapy after sirolimus-eluting stent implantation is relatively common and carries a risk of late stent thrombosis.
Answers are grounded in this paper and cite their sources.
Supports vigilance against early antiplatelet discontinuation after sirolimus-eluting stents; leaves open optimal duration and adherence strategies in larger cohorts.
BACKGROUND: Antiplatelet therapy in patients with sirolimus-eluting stents (SES) may be stopped because of bleeding or an invasive procedure. METHODS AND RESULTS: In 254 patients with SES, the incidence of discontinuation of antiplatelet therapy and subsequent adverse cardiac events was evaluated. Follow-up was complete for 97.2% of the population and mean follow-up was 15.6+/-8.9 months. Discontinuation of antiplatelet therapy occurred for 46 patients (18.1%): 1 case of late stent thrombosis (2.2%) occurred 10 days after cessation of therapy because of pulmonary hemorrhage 7 months after SES deployment. CONCLUSION: Discontinuation of antiplatelet therapy in patients with SES is not infrequent.
No takes yet. Share an insight, caveat, or question.
Iwata et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: